Navigation Links
Repligen Announces Conference Call of Third Quarter Fiscal Year 2009 Results
Date:1/29/2009

Thursday, February 5th, 10:00 a.m. EST

WALTHAM, Mass., Jan. 29 /PRNewswire-FirstCall/ -- Repligen Corporation (Nasdaq: RGEN) announced today that the Company President and Chief Executive Officer, Walter C. Herlihy, Ph.D., will host a conference call and webcast on Thursday, February 5th, 2009 at 10:00 a.m. EST, to report third quarter fiscal year 2009 financial results and to provide a quarterly update of the Company.

This call is being webcast by Thomson/CCBN and can be accessed via Repligen's website at www.repligen.com. If you are unable to access the webcast via the internet, you may also listen to the live broadcast by calling (866) 383-8008 for domestic calls and (617) 597-5341 for international calls. Participants must provide the following passcode: 88957320. For those who cannot participate in the live conference call, an archive of the audio webcast will be available shortly after the call and may be accessed at www.repligen.com.

About Repligen Corporation

Repligen Corporation is a biopharmaceutical company focused on the development of novel therapeutics for neurological disorders. In addition, we are the world's leading supplier of recombinant Protein A, the sales of which partially fund the advancement of our development pipeline while supporting our financial stability. Repligen's corporate headquarters are located at 41 Seyon Street, Building #1, Suite 100, Waltham, MA 02453. Additional information may be requested from www.repligen.com.

This press release contains forward-looking statements which are made pursuant to the safe harbor provisions of Section 27A of the Securities
'/>"/>

SOURCE Repligen Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Repligen to Present at the Rodman & Renshaw 10th Annual Healthcare Conference Monday, November 10th, 4:55 p.m. EST
2. Repligen to Present at the 2008 UBS Global Life Sciences Conference Wednesday, September 24th, 1:00 p.m. EDT
3. Repligen Announces Publication of Positive Results with Proprietary HDAC Inhibitor in Huntingtons Disease Model
4. Repligen Receives Research Grants to Support Friedreichs Ataxia Development Program
5. Repligen Announces Conference Call of First Quarter Fiscal Year 2009 Results
6. Repligen Reports Fourth Quarter and Fiscal Year 2008 Financial Results
7. Repligen Announces Settlement with Bristol-Myers Squibb in Orencia(R) Lawsuit
8. Repligen Announces Conference Call of Third Quarter Fiscal Year 2008 Results
9. Omnitura Therapeutics Announces Private Placement Financing
10. Amicus Therapeutics Announces Fourth Quarter and Year End 2008 Financial Results Release Date
11. Sangamo BioSciences Announces Fourth Quarter and Year-End 2008 Conference Call and Webcast
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2015)... 2015 Biovista Inc. is glad ... 2015 BeHEARD science challenge, a global competition hosted by ... access to the latest life science innovations and technologies. ... pathway analytics capability to support Steven Laffoon ... study of Niemann-Pick Disease Type A (NPA), a rare ...
(Date:9/2/2015)...  Neurotech Pharmaceuticals, Inc., announced today the first ... 2 clinical trial of NT-503 Encapsulated Cell Therapy ... choroidal neovascularization secondary to age related macular degeneration ... growth factor (VEGF) receptor protein continuously produced by ... proof-of-concept study will evaluate NT-503 ECT as a ...
(Date:9/2/2015)... Sept. 2, 2015 Aytu BioScience, Inc. (OTCQB: ... for urological and related conditions, announced today that it ... placement convertible note financing, raising a total of $5.175 ... $3.175 million. Josh Disbrow , ... private placement are intended to be used to conduct ...
(Date:9/2/2015)... , September 2, 2015 ... BOLT) ("BioLight" or the "Company"), a firm that ... ophthalmology and cancer diagnostics, announced today that presentations ... glaucoma will be delivered at the Ophthalmology Futures ... European Society of Cataract & Refractive Surgeons ("ESCRS"), ...
Breaking Biology Technology:Biovista Sponsors Wylder Nation Foundation's Research on Acid Sphingomyelinase Deficiency 2Neurotech Announces First Patient Enrolled in Novel Anti-VEGF Encapsulated Cell Therapy Study 2Neurotech Announces First Patient Enrolled in Novel Anti-VEGF Encapsulated Cell Therapy Study 3Neurotech Announces First Patient Enrolled in Novel Anti-VEGF Encapsulated Cell Therapy Study 4Aytu BioScience Completes $5.175 Million Private Placement 2Aytu BioScience Completes $5.175 Million Private Placement 3Presentations to Highlight BioLight's IOPtiMate[TM] System at Upcoming European Ophthalmology Conferences 2Presentations to Highlight BioLight's IOPtiMate[TM] System at Upcoming European Ophthalmology Conferences 3
... Since Start of Q4 2008 , - Evaluation of strategic ... Board RoleSAN DIEGO, Jan. 5 ADVENTRX Pharmaceuticals, Inc. (NYSE ... further reduction-in-force in an effort to extend its remaining cash ... follows a reduction implemented in October 2008. In all, ...
... Jan. 5 Theodosius Dobzhansky, the late great geneticist ... makes sense except in the light of evolution."This year ... 1809) and the 150th anniversary of the publication of ... the theory of evolution by means of natural selection ...
... Requadt Promoted From PrincipalsCAMBRIDGE, Mass., and SOUTH SAN ... ("Clarus Ventures"), a leading life sciences venture capital ... M.D., Ph.D., M.P.H., to Partner and Scott Requadt, ... 2009.Dr. Cunningham joined Clarus in 2006 and represents ...
Cached Biology Technology:ADVENTRX Announces Further Cost-Cutting Measures 2ADVENTRX Announces Further Cost-Cutting Measures 3ADVENTRX Announces Further Cost-Cutting Measures 4ADVENTRX Announces Further Cost-Cutting Measures 5GEN Joins Charles Darwin 2009 Celebration 2Clarus Ventures Names Two New Partners 2Clarus Ventures Names Two New Partners 3
(Date:8/20/2015)... Aug. 20, 2015 The wearable technology ... are active and healthy. However, wearable technology has ... environment to help improve diagnostic capabilities and therapeutic ... the Wearable Technologies Conference 2015 , where ... for wearables in healthcare.    "Over ...
(Date:8/18/2015)... N.J. , Aug. 18, 2015 /PRNewswire/ ... a key contributor to the Submission Content ... by IRISS, a non-profit forum. Dedicated to the ... provides a neutral platform for industry, vendors, ... share information and work towards a standard ...
(Date:8/12/2015)... , August 12, 2015 As ... mobile payment innovation and advanced biometrics technology is accelerating ... way consumers rely on using their credit cards, the ... the future for payment services led by companies in ... ), :  Google, Inc. (NASDAQ: GOOG ), Apple ...
Breaking Biology News(10 mins):Leaf Healthcare Releases Video from Wearable Technology Conference on New Applications for Wearables in the Hospital Environment 2Leaf Healthcare Releases Video from Wearable Technology Conference on New Applications for Wearables in the Hospital Environment 3Navitas, a Key Contributor in IRISS Forum Webinar 2Navitas, a Key Contributor in IRISS Forum Webinar 3Digital Wallet Devices & Mobile Payment Management Services Gain a Distinct Advantage in the Digital Payment Evolution as Demand Continues to Grow 2Digital Wallet Devices & Mobile Payment Management Services Gain a Distinct Advantage in the Digital Payment Evolution as Demand Continues to Grow 3Digital Wallet Devices & Mobile Payment Management Services Gain a Distinct Advantage in the Digital Payment Evolution as Demand Continues to Grow 4Digital Wallet Devices & Mobile Payment Management Services Gain a Distinct Advantage in the Digital Payment Evolution as Demand Continues to Grow 5Digital Wallet Devices & Mobile Payment Management Services Gain a Distinct Advantage in the Digital Payment Evolution as Demand Continues to Grow 6
... to America,s health! Water is essential to life, and ... drinking water safe from pathogens and other waterborne contaminants. ... research grants to four universities, one non-profit, and one ... emerging drinking water contaminants; including the harmful substances produced ...
... of Cincinnati (UC) implicates the primary chemical used to ... metabolic syndrome and its consequences. In a laboratory ... found that BPA suppresses a key hormone, adiponectin, which ... and puts people at a substantially higher risk for ...
... in German . , Cystic kidney disease, ... the excretory organs are characterized by overproduction or ... the renal cells. An international research team under the ... has now developed an animal model to better investigate ...
Cached Biology News:To your health: EPA announces safe drinking water research 2Bisphenol A linked to metabolic syndrome in human tissue 2Gaining a better understanding of kidney diseases 2
...
... in two product models - the 5000AT+ and ... that the 6000AT+ includes a membrane desolvation unit ... improved detection limits and reduced oxides. The Ultrasonic ... elements by 10-40 times. Note that with ICP-MS ...
...
... Ultrasonic Nebulizers are available in two product models ... these two models is that the 6000AT+ includes ... a drier aerosol for improved detection limits and ... for a range of elements by 10-40 times. ...
Biology Products: